The 2025 AAD Meeting features key psoriasis sessions on therapies, JAK inhibitors, obesity links, patient care gaps, and cutting-edge treatment advances.

Geeta Yadav, MD, and colleagues used a Canadian Delphi consensus to produce guidelines to optimize psoriasis management in patients with skin of color.

In a recent session at the 2025 Winter Clinical meeting in Hawaii, presenters shared how dermatologists can add or alter treatments to improve response.

Research published in JAMA Dermatology indicated that home-based phototherapy was as effective as office-based phototherapy for patients with psoriasis.

Findings from the VISIBLE trial will help address gaps in psoriasis care for patients with skin of color and inform best practices to drive inclusive research.

The TELEPROM Psoriasis study highlights how telepharmacy and patient-reported outcomes improve the quality of life for patients with moderate-to-severe psoriasis.

On Tuesday, January 21, 2025, Joel Gelfand, MD, will join a panel of speakers to discuss the changing landscape of psoriasis and psoriatic arthritis.

Amy Huang, MD, spoke with Physician’s Weekly about the non-pharmacologic options for managing comorbidities in patients with psoriasis.